Mirvetuximab Signals a New Era in Ovarian Care
Antibody-drug conjugates (ADCs) are revolutionizing the treatment of ovarian cancer, particularly with the approval of mirvetuximab soravtansine for platinum-resistant cases. This therapy has shown a significant improvement in overall survival compared to traditional chemotherapies. As more ADCs are developed, they may offer new hope for patients with specific tumor markers.
- ▪Mirvetuximab soravtansine is the only ADC approved for platinum-resistant ovarian cancer.
- ▪The treatment has demonstrated a meaningful improvement in overall survival and tumor reduction.
- ▪Common adverse effects include ocular toxicity, nausea, and fatigue.
Opening excerpt (first ~120 words) tap to expand
Antibody‑drug conjugates (ADCs) enhance tumor control and patients’ quality of life and have demonstrated a measurable benefit in overall survival.As the world marks World Ovarian Cancer Day (May 8, 2026), ADCs are emerging as a major hope that is changing the approach to this disease. The original text reported about 3800 new diagnoses and roughly 2000 deaths last year; the geographic scope of these figures was not specified in the source. ADCs target the folate receptor alpha (FR alpha) protein, which is expressed particularly strongly in about 40% of cases of the most common ovarian cancer subtype, high‑grade serous carcinoma.Mirvetuximab soravtansine is currently the only ADC approved for platinum‑resistant ovarian cancer.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
